Galcanezumab

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Migraine

Drug Information

Target Indication

Chronic Migraine

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA11/14/2018

Emgality

Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Related Pipeline

Growth Disorder

Type 1 Diabetes Mellitus

Obesity

Attention Deficit Hyperactivity Disorder

Major Depressive Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts